Evogene Ltd.
EVGN
Price:
$2.09
Market Cap:
$11.21M
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develo...[Read more]
Industry
Biotechnology
IPO Date
2010-10-15
Stock Exchange
NASDAQ
Ticker
EVGN
PE Ratio
[-0.54]
ROE
[-189.58%]
Current Ratio
[4.37]
Dividend Yield
[0%]
Enterprise Value
[2.54M]
Dividend History
The ROE as of November 2024 (TTM) for Evogene Ltd. (EVGN) is -189.58%
According to Evogene Ltd.’s latest financial reports and current stock price. The company's current ROE is -189.58%. This represents a change of 153.12% compared to the average of -74.90% of the last 4 quarters.
Evogene Ltd. (EVGN) Historical ROE (quarterly & annually)
How has EVGN ROE performed in the past?
The mean historical ROE of Evogene Ltd. over the last ten years is -55.49%. The current -189.58% ROE has changed 241.65% with respect to the historical average. Over the past ten years (40 quarters), EVGN's ROE was at its highest in in the March 2015 quarter at -3.00%. The ROE was at its lowest in in the June 2024 quarter at -176.69%.
Average
-55.49%
Median
-38.80%
Minimum
-198.12%
Maximum
-12.52%
Evogene Ltd. (EVGN) ROE by Quarter and Year
Discovering the peaks and valleys of Evogene Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 107.73%
Maximum Annual ROE = -12.52%
Minimum Annual Increase = -12.91%
Minimum Annual ROE = -198.12%
| Year | ROE | Change |
|---|---|---|
| 2023 | -198.12% | 107.73% |
| 2022 | -95.37% | 85.41% |
| 2021 | -51.44% | 1.33% |
| 2020 | -50.76% | 40.54% |
| 2019 | -36.12% | -12.91% |
| 2018 | -41.47% | 38.08% |
| 2017 | -30.04% | 33.82% |
| 2016 | -22.44% | 35.29% |
| 2015 | -16.59% | 32.54% |
| 2014 | -12.52% | 75.88% |
Evogene Ltd. (EVGN) Average ROE
How has EVGN ROE performed in the past?
The current ROE of Evogene Ltd. (EVGN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-114.98%
5-year avg
-86.36%
10-year avg
-55.49%
Evogene Ltd. (EVGN) ROE vs. Peers
How is EVGN’s ROE compared to its peers?
Evogene Ltd.’s ROE is greater than Arcus Biosciences, Inc. (-42.86%), greater than Fate Therapeutics, Inc. (-44.09%), greater than Surface Oncology, Inc. (-113.52%), greater than Pluri Inc. (-482.73%), greater than Lexaria Bioscience Corp. (-82.80%), greater than Navidea Biopharmaceuticals, Inc. (-173.56%), greater than ZyVersa Therapeutics, Inc. (-172.51%), greater than Biodexa Pharmaceuticals Plc (-101.74%), greater than Oncorus, Inc. (-130.61%), greater than Can-Fite BioPharma Ltd. (-179.39%), greater than ImmuCell Corporation (-16.35%), greater than Compugen Ltd. (-16.10%), greater than CollPlant Biotechnologies Ltd. (-65.98%), less than Protalix BioTherapeutics, Inc. (0%), greater than Corvus Pharmaceuticals, Inc. (-45.15%), greater than Aldeyra Therapeutics, Inc. (-53.99%), greater than Gamida Cell Ltd. (-33.33%), less than Checkpoint Therapeutics, Inc. (187.96%), less than null (292.43%),
| Company | ROE | Market cap |
|---|---|---|
| -42.86% | $1.42B | |
| -44.09% | $314.30M | |
| -113.52% | $65.08M | |
| -482.73% | $24.94M | |
| -82.80% | $39.79M | |
| -173.56% | $50.04K | |
| -172.51% | $1.96M | |
| -101.74% | $3.30M | |
| -130.61% | $3.14M | |
| -179.39% | $15.23M | |
| -16.35% | $28.12M | |
| -16.10% | $146.84M | |
| -65.98% | $42.50M | |
| 0% | $94.13M | |
| -45.15% | $564.21M | |
| -53.99% | $307.80M | |
| -33.33% | $4.34M | |
| 187.96% | $154.67M | |
| 292.43% | $0 |
Build a custom stock screener for Evogene Ltd. (EVGN) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Evogene Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Evogene Ltd. (EVGN) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Evogene Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Evogene Ltd.'s ROE?
How is the ROE calculated for Evogene Ltd. (EVGN)?
What is the highest ROE for Evogene Ltd. (EVGN)?
What is the 3-year average ROE for Evogene Ltd. (EVGN)?
What is the 5-year average ROE for Evogene Ltd. (EVGN)?
How does the current ROE for Evogene Ltd. (EVGN) compare to its historical average?